Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 331

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 331
---
 Management used a scenario-based analysis to estimate the fair value of the bifurcated embedded derivative liability at issuance of the Notes. The Company recognized debt discount of $ 2,539,227upon issuance of the notes. See note 5 on the fair value of the derivative liability. F-8 5

TUHURA BIOSCIENCES, INC AND SUBSIDIARIES Notes to the consolidated financial statements For the years ended December 31, 2024, and 2023

Warrants issued in connection with convertible notes

The 2024 Warrants were identified as freestanding financial instruments and determined to be indexed to the Company’s own stock. Further, the 2024 Warrants were not precluded from being classified within equity. As such, the proceeds received upon issuing the Notes were first allocated to the fair value of the bifurcated embedded derivative with the remainder allocated to the debt host instrument and 2024 Warrants (within additional paid in capital) on a relative fair value basis. Subsequent fair value measurement is not required as long as the instrument continues to be classified in equity. The Company determined that the fair value of the 2024 Warrants in connection with Notes issued amounted to $ 6,520,056 and recognized as a debt discount with an offset to additional paid in capital.

Convertible notes and debt discount

Convertible notes issued (including accrued interest) outstanding, and converted are as follows:

| Balance as of January 1, 2023         |     | Convertible notespayable |           — |   |
|:--------------------------------------|:----|:-------------------------|------------:|:--|
| Issuance of convertible notes payable |     |                          |   2,685,000 |   |
| Interest expense                      |     |                          |      13,564 |   |
| Balance as of December 31, 2023       |     | $                        |   2,698,564 |   |
| Issuance of convertible notes payable |     |                          |  28,568,000 |   |
| Interest expense                      |     |                          |   2,859,878 |   |
| Converted to common stock             |     |                          | (34,126,442 | ) |
| Balance as of December 31, 2024       |     | $                        |           — |   |

Debt discount related to the convertible notes are as follows:

| Balance as of January 1, 202